<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; EMA</title>
	<atom:link href="http://www.tapanray.in/tag/ema/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Even Smaller Countries Now Question Indian Drug Quality Standard</title>
		<link>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=even-smaller-countries-now-question-indian-drug-quality-standard</link>
		<comments>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/#comments</comments>
		<pubDate>Sun, 04 Dec 2016 23:42:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bans]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[domestic]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[smaller]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Vietnam]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8001</guid>
		<description><![CDATA[India has over 135 US-FDA approved pharmaceutical manufacturing units, at present. This number is very significant ranking second behind the United States, and was driving the growth of generic drug exports in the top pharma market of the world. Riding &#8230; <a href="http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/even-smaller-countries-now-question-indian-drug-quality-standard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does India Produce ‘World Class’ Medicines, For All?</title>
		<link>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-produce-world-class-medicines-for-all</link>
		<comments>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/#comments</comments>
		<pubDate>Mon, 12 Oct 2015 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['import bans']]></category>
		<category><![CDATA['pharmacy of the world']]></category>
		<category><![CDATA[anti-epileptic]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Biosciences]]></category>
		<category><![CDATA[class]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Elepsia XR]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[NBER]]></category>
		<category><![CDATA[numero uno]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[quality. cGMP]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SPARC]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7160</guid>
		<description><![CDATA[India has already achieved a staggering number In terms of quantity or volume of generic medicines that it produces not just for India, but for many developed, developing and poorer countries, across the world. For this reason, India is popularly &#8230; <a href="http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data Manipulation: Leapfrogging Dangerously Into Clinical Trial Domain</title>
		<link>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain</link>
		<comments>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/#comments</comments>
		<pubDate>Mon, 03 Aug 2015 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[700]]></category>
		<category><![CDATA[Aurobindo]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jugaad]]></category>
		<category><![CDATA[Leapfrog]]></category>
		<category><![CDATA[Leapfrogging]]></category>
		<category><![CDATA[lifesciences]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[Malpractice]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharmexcil]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[quest]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rigmarole]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6908</guid>
		<description><![CDATA[Over the last several years, repeated allegations of gross data manipulative practices, detected by global drug regulatory agencies, such as USFDA and MHRA, have shaken the Indian pharma exporting companies hard. This has been hurting the overall business performance of &#8230; <a href="http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-manipulation-leapfrogging-dangerously-into-clinical-trial-domain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Outlook 2015: A Glimpse Of Some Drivers and Barriers</title>
		<link>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers</link>
		<comments>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/#comments</comments>
		<pubDate>Mon, 05 Jan 2015 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[exports]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Lantus]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Nadda]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6291</guid>
		<description><![CDATA[Looking ahead, the brand new year 2015 appears quite interesting to me both from the global and also from the local pharmaceutical industry perspective. In this article I shall try to give a glimpse of some of the important drivers &#8230; <a href="http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-outlook-2015-a-glimpse-of-some-drivers-and-barriers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would ‘Regenerative Medicine’ Shape The Future Of Global Healthcare?</title>
		<link>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-regenerative-medicine-shape-the-future-of-global-healthcare</link>
		<comments>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/#comments</comments>
		<pubDate>Mon, 22 Dec 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[Chiesi Farmaceutici]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Embryonic]]></category>
		<category><![CDATA[European Medicine Agency]]></category>
		<category><![CDATA[Holoclar]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Limbal]]></category>
		<category><![CDATA[LSCD]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regenerative medicine]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Shankara netralaya]]></category>
		<category><![CDATA[stem cells]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Type I]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6274</guid>
		<description><![CDATA[Just the last week, on December 19, 2014, international media broke the news of regulatory approval of the first stem cell treatment by the European Medicines Agency (EMA). The Agency reportedly has recommended an Orphan Drug &#8211; Holoclar of the &#8230; <a href="http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Scandalizing Biosimilar Drugs With Safety Concerns</title>
		<link>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scandalizing-biosimilar-drugs-with-safety-concerns</link>
		<comments>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/#comments</comments>
		<pubDate>Mon, 25 Aug 2014 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12]]></category>
		<category><![CDATA[badmouthing]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GPhA]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5772</guid>
		<description><![CDATA[With the patent expiry of exorbitantly priced biologic medicines, introduction of biosimilar drugs are expected to improve their access to millions of patients across the world, saving billions of dollars in healthcare costs in the subsequent years. According to an &#8230; <a href="http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs From The Same Indian Plant: Safe For Europe, Unsafe For America, Why?</title>
		<link>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why</link>
		<comments>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/#comments</comments>
		<pubDate>Mon, 09 Jun 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[conspiracy]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plant]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[unsafe]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[why]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5493</guid>
		<description><![CDATA[Good number of stories on US-FDA banning several drug manufacturing facilities of major domestic players of India over serious quality related issues, have been doing the rounds since about a year and almost at a regular interval. The quagmire has &#8230; <a href="http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Transparency in Drug Trial Data: Thwarted by Lobbyists or Embroiled in Controversy?</title>
		<link>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy</link>
		<comments>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/#comments</comments>
		<pubDate>Mon, 05 Aug 2013 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[Arguments]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[bodies]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[controversy]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[embroiled]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hardcore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[Jikei]]></category>
		<category><![CDATA[Laudable]]></category>
		<category><![CDATA[manipulation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mobilizing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[poignant]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[thwarted]]></category>
		<category><![CDATA[thwarting]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[University]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3274</guid>
		<description><![CDATA[Based on a leaked letter from overseas pharma industry bodies, a leading international daily in late July 2013 reported: “Big pharma mobilizing patients in battle over drugs trials data.” Some experts consider it as a poignant, if not a bizarre &#8230; <a href="http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/transparency-in-drug-trial-data-thwarted-by-lobbyists-or-embroiled-in-controversy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
